Europe - EPA:ALTME - NL0015000YE1 - Common Stock
The current stock price of ALTME.PA is 0.0944 EUR. In the past month the price decreased by -10.94%. In the past year, price decreased by -27.27%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 22.02 | 355.96B | ||
1ABBV.MI | ABBVIE INC | 21.97 | 355.08B | ||
AMG.DE | AMGEN INC | 13.5 | 136.99B | ||
GIS.DE | GILEAD SCIENCES INC | 15.19 | 126.07B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 24.14 | 90.61B | ||
1AE.DE | ARGENX SE | 93.04 | 42.53B | ||
ARGX.BR | ARGENX SE | 91.99 | 42.06B | ||
1INSM.MI | INSMED INC | N/A | 29.80B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 21.09B | ||
IDP.DE | BIOGEN INC | 9.18 | 18.63B | ||
1EXAS.MI | EXACT SCIENCES CORP | N/A | 9.34B | ||
1MRNA.MI | MODERNA INC | N/A | 9.25B |
TME Pharma NV is a clinical-stage biopharmaceutical company, which focuses on therapeutics targeting the tumor microenvironment or TME. The company is headquartered in Berlin, Berlin and currently employs 12 full-time employees. The company went IPO on 2018-09-10. The firm specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. their clinical programs in glioblastoma and pancreatic cancer have delivered results and further development is planned.
TME PHARMA NV
Max-Dohrn-Str. 8-10
Berlin BERLIN DE
Employees: 12
Phone: 49307262470
The current stock price of ALTME.PA is 0.0944 EUR. The price decreased by -3.18% in the last trading session.
The exchange symbol of TME PHARMA NV is ALTME and it is listed on the Euronext Paris - Matif exchange.
ALTME.PA stock is listed on the Euronext Paris - Matif exchange.
9 analysts have analysed ALTME.PA and the average price target is 0.36 EUR. This implies a price increase of 285.2% is expected in the next year compared to the current price of 0.0944. Check the TME PHARMA NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TME PHARMA NV (ALTME.PA) has a market capitalization of 8.89M EUR. This makes ALTME.PA a Nano Cap stock.
TME PHARMA NV (ALTME.PA) currently has 12 employees.
TME PHARMA NV (ALTME.PA) has a resistance level at 0.1. Check the full technical report for a detailed analysis of ALTME.PA support and resistance levels.
The Revenue of TME PHARMA NV (ALTME.PA) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ALTME.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALTME.PA does not pay a dividend.
TME PHARMA NV (ALTME.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.17).
ChartMill assigns a fundamental rating of 2 / 10 to ALTME.PA. ALTME.PA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months ALTME.PA reported a non-GAAP Earnings per Share(EPS) of -0.17. The EPS increased by 88.76% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -168% | ||
ROE | -354.52% | ||
Debt/Equity | 0 |
9 analysts have analysed ALTME.PA and the average price target is 0.36 EUR. This implies a price increase of 285.2% is expected in the next year compared to the current price of 0.0944.
For the next year, analysts expect an EPS growth of 89.47% and a revenue growth -100% for ALTME.PA